Racura Oncology (ASX:RAC): One drug, three shots
Venn Brown sat down with Daniel Tillett, CEO of Racura Oncology, to discuss the three potential applications for RC220, their potential market...
111 Views
Primer: Race Oncology (RAC AU) - May 2026
Race Oncology is a clinical-stage biopharmaceutical company focused on the redevelopment of a historically de-risked oncology drug, Zantrene...
119 Views
Race Oncology Ltd - Pursuing a Three-Pillar Strategy to Treat Cancer
Race Oncology Ltd Pursuing a three-pillar strategy to treat cancer Race Oncology Ltd (ASX:RAC) is a precision oncology company which listed...
963 Views
Rediscovering a lost chemotherapeutic
Race Oncology is currently focused on the development of bisantrene, which had been the subject of over 40 clinical trials in the 1980s and 1990s...
165 Views